Abstract
Background
To report a case of nonarteritic anterior ischemic optic neuropathy (NA-AION) following intravitreal injection of bevacizumab (Avastin®).
Methods
Interventional case report with an 18-month follow-up.
Results
A 51-year-old male with pseudoxanthoma elasticum presented with NA-AION 2 weeks after treatment with intravitreal of bevazicumab (Avastin®) for choroidal neovascularisation secondary to angioid streaks. Except from a small optic disc without cupping he did not show further risk factors.
Discussion
Risk of NA-AION should be taken into consideration when deciding for intravitreal application of drugs including anti-vascular endothelial growth factors (VEGF) agents like bevacizumab (Avastin®) in the treatment of retinal vascular diseases.
This is a preview of subscription content, log in via an institution to check access.
References
Bhatnagar P, Freund KB, Spaide RF, Klancnik JM Jr, Cooney MJ, Ho I, Fine HF, Yannuzzi LA (2007) Intravitreal bevacizumab for the management of choroidal neovascularization in pseudoxanthoma elasticum. Retina 27:897–902
Rinaldi M, Dell'Omo R, Romano MR, Chiosi F, Cipollone U, Costagliola C (2007) Intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks. Arch Ophthalmol 125:1422–1423
Teixeira A, Moraes N, Farah ME, Bonomo PP (2006) Choroidal neovascularization treated with intravitreal injection of bevacizumab (Avastin) in angioid streaks. Acta Ophthalmol Scand 84:835–836
Sachdev N, Vishwanathan K, Gupta V, Singh R, Gupta A (2007) Intravitreal bevacizumab (Avastin) in choroidal neovascular membrane in angioid streaks. Indian J Ophthalmol 55:457–458
Lommatzsch A, Spital G, Trieschmann M, Pauleikhoff D (2007) Intraocular application of bevacizumab for the treatment of choroidal neovascularization secondary to angioid streaks. Ophthalmologe 104:325–328
Wu L, Martinez-Castellanos MA, Quiroz-Mercado H et al (2008) Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): Results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246:81–87
Hayreh SS, Zimmerman MB (2007) Incipient nonarteritic anterior ischemic optic neuropathy. Ophthalmology 114:1763–1772
Ziemssen F, Bartz-Schmidt KU, Grisanti S (2006) (Neben)-Wirkungen der VEGF-inhibition. Ophthalmologe 130:484–490
Newman NJ (2007) The ischemic optic neuropathy decompression trail. Arch Ophthalmol 125:1568–1570
Wilhelm B, Lüdtke H, Wilhelm H (2006) BRAION Study Group: Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (N-AION): A 3-month, double-masked, randomised, placebo-controlled trial. Graefes Arch Clin Exp Ophthalmol 244:551–558
Hayreh SS (2009) Ischemic optic neuropathy. Prog Retin Eye Res 28:34–62
Hayreh SS, Zimmerman MB (2008) Non-arteritic anterior ischemic: role of systemic corticosteroid therapy. Graefes Arch Clin Exp Ophthalmol 246:1029–1046
Bennett JL, Thomas S, Olson JL, Mandava N (2007) Treatment of nonarteritic anterior ischemic optic neuropathy with intravitreal bevacizumab. J Neuroophthalmol 27:238–240
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ganssauge, M., Wilhelm, H., Bartz-Schmidt, KU. et al. Non-arteritic anterior ischemic optic neuropathy (NA-AION) after intravitreal injection of bevacizumab (Avastin®) for treatment of angoid streaks in pseudoxanthoma elasticum. Graefes Arch Clin Exp Ophthalmol 247, 1707–1710 (2009). https://doi.org/10.1007/s00417-009-1184-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-009-1184-5